BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Sold by Jane Street Group LLC

Jane Street Group LLC reduced its stake in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) by 60.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,317 shares of the company’s stock after selling 75,729 shares during the period. Jane Street Group LLC owned about 0.12% of BioXcel Therapeutics worth $30,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. XTX Topco Ltd lifted its position in shares of BioXcel Therapeutics by 49.0% during the second quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock worth $60,000 after purchasing an additional 15,291 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BioXcel Therapeutics during the second quarter valued at approximately $39,000. Finally, Armistice Capital LLC lifted its holdings in BioXcel Therapeutics by 705.2% during the 2nd quarter. Armistice Capital LLC now owns 2,987,000 shares of the company’s stock worth $3,823,000 after buying an additional 2,616,027 shares during the last quarter. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Trading Down 0.2 %

Shares of NASDAQ BTAI opened at $0.35 on Friday. The company has a market cap of $17.16 million, a price-to-earnings ratio of -0.16 and a beta of -0.01. The stock’s 50 day simple moving average is $0.45 and its 200 day simple moving average is $0.66. BioXcel Therapeutics, Inc. has a 12-month low of $0.30 and a 12-month high of $4.17.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BTAI shares. Bank of America reiterated an “underperform” rating and issued a $0.25 price target (down from $7.00) on shares of BioXcel Therapeutics in a report on Tuesday, January 7th. Canaccord Genuity Group dropped their target price on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, HC Wainwright reduced their price target on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, October 21st.

BioXcel Therapeutics Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.